US OptionsDetailed Quotes
VSTM240816C5000
- 0.35
- 0.000.00%
15min DelayClose Aug 9 09:50 ET
0.00High0.00Low
0.35Open0.35Pre Close0 Volume104 Open Interest5.00Strike Price0.00Turnover695.58%IV127.66%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.3632Delta0.1722Gamma6.71Leverage Ratio-0.0644Theta0.0001Rho2.44Eff Leverage0.0012Vega
Verastem Stock Discussion
Sign in to post a comment
$Verastem (VSTM.US)$
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
Verastem Oncology (Nasdaq: VSTM) has received FDA Orphan Drug Designation for avutometinib and defactinib in treating pancreatic cancer. This combination therapy, along with standard chemotherapy, showed promising results in the ongoing RAMP 205 trial for first-line metastatic pancreatic cancer. Initial interim data presented at ASCO 2024 revealed ...
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
Verastem Oncology (Nasdaq: VSTM) has received FDA Orphan Drug Designation for avutometinib and defactinib in treating pancreatic cancer. This combination therapy, along with standard chemotherapy, showed promising results in the ongoing RAMP 205 trial for first-line metastatic pancreatic cancer. Initial interim data presented at ASCO 2024 revealed ...
1
5
$Verastem (VSTM.US)$
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
Verastem Oncology (Nasdaq: VSTM) has announced the pricing of a $55.0 million public offering of common stock, warrants, and pre-funded warrants. The offering includes 13,333,334 shares of common stock and warrants at $3.00 per share, and 5,000,000 pre-funded warrants with accompanying warrants at $2.999 each. The warrants have an exercise price of $3.50 ...
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
Verastem Oncology (Nasdaq: VSTM) has announced the pricing of a $55.0 million public offering of common stock, warrants, and pre-funded warrants. The offering includes 13,333,334 shares of common stock and warrants at $3.00 per share, and 5,000,000 pre-funded warrants with accompanying warrants at $2.999 each. The warrants have an exercise price of $3.50 ...
$Verastem (VSTM.US)$ another public offering, better stay out for company keep raising cash!
$Verastem (VSTM.US)$ wtf, go to penny please. the broad is rubbish
1
Verastem Oncology Announces First Patient Dosed in Phase 1/2 Trial of GFH375/VS-7375 in China.
Verastem Oncology, a biopharmaceutical company listed on Nasdaq under the ticker VSTM, has recently announced the commencement of dosing for the first patient in a Phase 1/2 clinical trial in China. This trial, conducted by GenFleet Therapeutics, aims to evaluate GFH375/VS-7375, a novel KRAS G12D (ON/OFF) inhibitor. $Verastem (VSTM.US)$
...
Verastem Oncology, a biopharmaceutical company listed on Nasdaq under the ticker VSTM, has recently announced the commencement of dosing for the first patient in a Phase 1/2 clinical trial in China. This trial, conducted by GenFleet Therapeutics, aims to evaluate GFH375/VS-7375, a novel KRAS G12D (ON/OFF) inhibitor. $Verastem (VSTM.US)$
...
2
$Verastem (VSTM.US)$ target price is $18. i hope this run!
1
$Verastem (VSTM.US)$
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China. Conducted by GenFleet Therapeutics, this trial is part of a collaboration established in 2023. The trial aims to evaluate GFH375...
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) inhibitor, in a Phase 1/2 trial in China. Conducted by GenFleet Therapeutics, this trial is part of a collaboration established in 2023. The trial aims to evaluate GFH375...
1
$Verastem (VSTM.US)$ Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $18
储亿银行维持Verastem(VSTM.US)买入评级，目标价18美元
储亿银行维持Verastem(VSTM.US)买入评级，目标价18美元
1
1
1
1
No comment yet
Salmon Klein : great news!! isn't?!
151323992 : Like with that news it should be on a rampage....
151323992 : This won't go up until a clinical trial takes place I assume
Jaguar8 OP 151323992 : It already has clinical trial data to support an ODD.
Salmon Klein Jaguar8 OP : why the negative reaction today? I was in a few days ago at 3... should have sold yesterday?....I personally like this stock, financials are healthy, clinical results seems going well...what's your view here?